Tags : MSD

Weekly Snapshot

PharmaShots Weekly Snapshots (June 21 – 25, 2021)

Regeneron and Sanofi’s Libtayo (cemiplimab) Receive the EC’s Approval as 1L Treatment for Advanced Basal Cell Carcinoma Published: June 25, 2021 | Tags: Regeneron, Sanofi, Libtayo, cemiplimab, EC, Approval, Advanced Basal Cell Carcinoma Regeneron and Sanofi’s Libtayo (cemiplimab) Receive the EC’s Approval as 1L Treatment for Advanced NSCLC Published: June 25, 2021 | Tags: Regeneron, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 26 – 30, 2021)

BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority Review, nivolumab, Muscle Invasive Urothelial Carcinoma Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma Published: Apr 30, 2021 | […]Read More

Clinical Trials Regulatory

Sanofi Entered into an Agreement with Merck to Conduct a

Shots: Sanofi will sponsor the clinical trials while MSD will provide KEYTRUDA. Additionally, Sanofi is separately evaluating the activity of THOR-707 in combination with other anti-PD-1 antibodies, including Libtayo (cemiplimab-rwlc) and with anti-EGFR and anti-CD38 antibodies for various types of cancer tumors In preclinical studies, THOR-707 demonstrated the ability to induce the expansion of CD8+T-cells […]Read More

Regulatory

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion

Shots: The CHMP has recommended the approval of Lynparza + bevacizumab for the 1L maintenance treatment of patients with HRD+ advanced ovarian cancer. The positive opinion is based on a biomarker subgroup analysis of P-III PAOLA-1 study The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. for newly diagnosed advanced FIGO […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Sept 14 -18, 2020)

1. AstraZeneca Reports Updated Results of Imfinzi in P-III Studies for NSCLC and ES-SCLC Published: Sept 18, 2020 | Tags:  AstraZeneca, Reports, Updated Results, Imfinzi, P-III, Studies, NSCLC, ES-SCLC 2. Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia Published: Sept 18, 2020 | Tags:  Roche, Actemra, EMPACTA study, […]Read More

Top 20

Top 20 Prescription Drugs Based on 2019 Revenue

The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More

Weekly Snapshot

Weekly Snapshot (Jul 06 – 10, 2020)

1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, FDA, Acceptance, BLA, Tralokinumab, Treat, Adults, Moderate to Severe, Atopic Dermatitis 2. Philips Collaborates with BioIntelliSense to Enhance Remote Patient Monitoring Published Date:  Jul 10, […]Read More